Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis
Por:
Silverberg JI, Wollenberg A, Stein Gold L, Yosipovitch G, Lio P, Vestergaard C, Ständer S, Carrascosa JM, Gallo G, Casillas M, Ding Y, Yang FE, Pierce E, Agell H and Del Rosso J
Publicada:
11 feb 2026
Ahead of Print:
1 feb 2026
Resumen:
Background Lebrikizumab, a novel monoclonal antibody targeting interleukin-13, demonstrated a durable and deep response on skin and itch in patients treated for 104 weeks in recent phase III trials (ADvocate1, NCT04146363; ADvocate2, NCT04178967; ADjoin, NCT04392154).Objectives To assess stability of response through 2 years of continuous lebrikizumab treatment in week 16 responders from ADvocate1 and ADvocate2 who continued the same treatment [lebrikizumab every 4 weeks (q4w), n = 99; lebrikizumab every 2 weeks (q2w), n = 82] in the long-term extension study ADjoin.Methods Week 16 response was defined as the Investigator's Global Assessment score of 0 or 1 with >= 2-point improvement from baseline, or >= 75% reduction in Eczema Area and Severity Index (EASI 75) without rescue medication. Stability was measured for EASI 75, EASI 90 and Pruritus Numeric Rating Scale (NRS) >= 3-point and >= 4-point improvement from baseline among week 16 responders who had achieved the specified endpoint at week 16. Stability was defined as maintenance of response for >= 80% of attended study visits from weeks 16 through 104 (ADjoin week 52). Observed data were analysed regardless of rescue medication or discontinuation from treatment.Results With 104 weeks of continuous lebrikizumab treatment, 96% and 81% of week 16 responders receiving lebrikizumab q4w (91% and 79% for q2w) showed stable EASI 75 and EASI 90 responses, respectively. Similarly, 94% and 88% of responders receiving lebrikizumab q4w (89% and 87% for q2w) showed stable responses for Pruritus NRS >= 3-point and >= 4-point improvement, respectively.Conclusions The majority of lebrikizumab week 16 responders maintained stable efficacy in measures of skin and itch during 2 years of treatment.
Lebrikizumab, a novel monoclonal antibody targeting interleukin-13, demonstrated a durable and deep response on skin and itch in patients treated for 104 weeks in recent phase III trials (ADvocate1, ADvocate2, ADjoin). This analysis assessed stability of response through 2 years of continuous lebrikizumab treatment in week 16 responders assessed by Investigator's Global Assessment, Eczema Area and Severity Index, and Pruritus Numeric Rating Scale. The results demonstrated that the majority of lebrikizumab week 16 responders maintained stable efficacy by measures of skin and itch during 2 years of treatment.
Filiaciones:
Silverberg JI:
George Washington University School of Medicine, Washington, DC, USA
Wollenberg A:
Department of Dermatology and Allergy, University Hospital Augsburg, Augsburg, Germany
Department of Dermatology and Allergy, Ludwig-Maximilian University, Munich, Germany
Comprehensive Center for Inflammation Medicine, University of Luebeck, Luebeck, Germany
Stein Gold L:
Henry Ford Health System, Detroit, MI, USA
Yosipovitch G:
Miller School Medicine, University of Miami, Miami, FL, USA
Lio P:
Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Vestergaard C:
Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark
Ständer S:
Center for Chronic Pruritus, University Hospital Münster, Münster, Germany
:
Universitat Autònoma de Barcelona, Barcelona, Spain
Gallo G:
Eli Lilly and Company, Indianapolis, IN, USA
Casillas M:
Eli Lilly and Company, Indianapolis, IN, USA
Ding Y:
Eli Lilly and Company, Indianapolis, IN, USA
Yang FE:
Eli Lilly and Company, Indianapolis, IN, USA
Pierce E:
Eli Lilly and Company, Indianapolis, IN, USA
Agell H:
Almirall S.A., Barcelona, Spain
Del Rosso J:
JDR Dermatology Research, Las Vegas, NV, USA
hybrid
|